Latest Healthcare News

Page 68 of 150
Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.
Ada Torres
Ada Torres
27 Aug 2025
Nova Eye Medical has delivered solid FY25 results, meeting sales guidance outside China and achieving six consecutive halves of growth in the US market. The company also improved gross margins and reduced cash burn, setting an optimistic tone for FY26 with breakeven EBITDA guidance.
Ada Torres
Ada Torres
27 Aug 2025
Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.
Ada Torres
Ada Torres
27 Aug 2025
Nova Eye Medical Limited reported a 25% increase in revenue to AUD 29.3 million for FY2025, driven by strong sales in its glaucoma surgical devices segment, yet posted a net loss after tax of AUD 9.1 million. The company raised AUD 6.2 million through a share placement to support growth initiatives.
Ada Torres
Ada Torres
27 Aug 2025
Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.
Ada Torres
Ada Torres
27 Aug 2025
Global Health Limited reports solid progress towards profitability in FY2025, driven by a 6% increase in subscription revenue and strategic AI integration across its healthcare platforms.
Ada Torres
Ada Torres
27 Aug 2025
Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.
Ada Torres
Ada Torres
27 Aug 2025
Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.
Ada Torres
Ada Torres
27 Aug 2025
Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.
Ada Torres
Ada Torres
27 Aug 2025
Optiscan Imaging Ltd has launched a fully underwritten $17.75 million entitlement offer to fund clinical trials and regulatory clearances for its medical devices, marking a pivotal step in its transition to a commercial medical device manufacturer.
Ada Torres
Ada Torres
27 Aug 2025
Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.
Ada Torres
Ada Torres
27 Aug 2025
NeuroScientific Biopharmaceuticals reports encouraging early clinical results for its StemSmart™ MSC therapy in preventing and treating kidney transplant rejection and injury.
Ada Torres
Ada Torres
27 Aug 2025